AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14522153 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for colorectal cancer
Number of subjects: 0
Study 14522153 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment life expectancy and survival in females from more-deprived areas
Number of subjects: 0
Study 14522153 — intervention group
Group type: COMPARATOR
Intervention: Socio-economic deprivation
Number of subjects: 0
Study 11120456 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior-modifying education
Number of subjects: 49
Study 8855394 — intervention group
Group type: EXPERIMENTAL
Intervention: intensive group (ultrasound imaging and continuous wave Doppler studies at 18, 24, 28, 34 and 38 weeks gestation)
Number of subjects: 2743
Study 8855394 — intervention group
Group type: EXPERIMENTAL
Intervention: intensive group
Number of subjects: 2743
Study 8855394 — intervention group
Group type: COMPARATOR
Intervention: regular group (single imaging examination at 18 weeks and further imaging scans only as clinically indicated)
Number of subjects: 2743
Study 1815001 — intervention group
Group type: EXPERIMENTAL
Intervention: Readables
Number of subjects: 0
Study 1815001 — intervention group
Group type: COMPARATOR
Intervention: Single vision reading lens (Control)
Number of subjects: 0
Study 6668565 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of sensation information
Number of subjects: 0
Study 6668565 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived control and distraction
Number of subjects: 0
Study 6668565 — intervention group
Group type: COMPARATOR
Intervention: Routine dentistry
Number of subjects: 0
Study 31056681 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (median 1.6 mg/L for dipyridamole; 7.4 mg/L for regadenoson)
Number of subjects: 6087
Study 31056681 — intervention group
Group type: COMPARATOR
Intervention: No caffeine (control)
Number of subjects: 6087
Study 31056681 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 6087
Study 28525981 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg orally 1 hour before anesthesia and Ramosetron 0.3 mg intravenously at the end of surgery (Group GR)
Number of subjects: 132
Study 28525981 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin 300 mg orally 1 hour before anesthesia (Group G)
Number of subjects: 132
Study 28525981 — intervention group
Group type: COMPARATOR
Intervention: Ramosetron 0.3 mg intravenously at the end of surgery (Group R)
Number of subjects: 132
Study 26375824 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid therapy (morphine equivalents)
Number of subjects: 81
Study 23417581 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-IP approach
Number of subjects: 108
Study 23417581 — intervention group
Group type: COMPARATOR
Intervention: SA-OOP approach
Number of subjects: 108
Study 20464539 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and E (VCE) administration before anesthesia with desflurane
Number of subjects: 40
Study 20464539 — intervention group
Group type: COMPARATOR
Intervention: Control group with desflurane anesthesia without VCE
Number of subjects: 40
Study 20464539 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and E (VCE) administration
Number of subjects: 40
Study 19816079 — intervention group
Group type: EXPERIMENTAL
Intervention: XM02
Number of subjects: 608
Study 19816079 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim
Number of subjects: 608
Study 17404193 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 130
Study 17404193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 15202986 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered message emphasizing personal responsibility
Number of subjects: 528
Study 15202986 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered message emphasizing social responsibility
Number of subjects: 528
Study 11518436 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental Enrichment (dynamic cognitive treatment)
Number of subjects: 58
Study 11518436 — intervention group
Group type: COMPARATOR
Intervention: Traditional occupational therapy methods (control group)
Number of subjects: 58
Study 9844792 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (10 mg/70 kg bolus and 3.5 mg/70 kg/hour for 4 hours)
Number of subjects: 20
Study 9844792 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine and M-6-G combination
Number of subjects: 20
Study 9844792 — intervention group
Group type: EXPERIMENTAL
Intervention: M-6-G (doses producing plasma concentrations identical, 2x, or 3x higher than morphine)
Number of subjects: 20
Study 9844792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8822914 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) at an initial dosage of 20 mg/kg/d for 6 months
Number of subjects: 25
Study 8822914 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 25
Study 2184135 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus poly(A).poly(U)
Number of subjects: 224
Study 2184135 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 224
Study 6788319 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (25 mg daily)
Number of subjects: 15
Study 6788319 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine (125 mg daily)
Number of subjects: 15
Study 6788319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30556414 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% spray plus twice‐daily phone call reminders
Number of subjects: 24
Study 30556414 — intervention group
Group type: COMPARATOR
Intervention: Desoximetasone 0.25% spray
Number of subjects: 24
Study 28576629 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic resistance treadmill training (n=12)
Number of subjects: 23
Study 28576629 — intervention group
Group type: COMPARATOR
Intervention: Robotic assistance treadmill training (n=11)
Number of subjects: 23
Study 27852718 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) consisting of 10 high-intensity (85-90% peak power output) and 10 low-intensity (20-25% peak power output) intervals, each lasting 1 minute, for 8 weeks, twice weekly.
Number of subjects: 510
Study 27852718 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity steady-state training (MISS) following usual care recommendations, adhering to UK guidelines (>20 minutes continuous exercise at 40-70% heart rate reserve), for 8 weeks, twice weekly.
Number of subjects: 510
Study 24628999 — intervention group
Group type: COMPARATOR
Intervention: Conventional corneal crosslinking (CXL; n = 30)
Number of subjects: 60
Study 24628999 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal crosslinking with mechanical compression (CRXL; n = 30)
Number of subjects: 60
Study 22541945 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-stiffness shoe
Number of subjects: 11
Study 22541945 — intervention group
Group type: COMPARATOR
Intervention: Constant-stiffness control shoe
Number of subjects: 11
Study 20424418 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 mg/m2/day biosynthetic GH
Number of subjects: 35
Study 20424418 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4 mg/m2/day biosynthetic GH
Number of subjects: 35
Study 17911178 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg TPTD
Number of subjects: 1620
Study 17911178 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microg TPTD
Number of subjects: 1620
Study 17911178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1620
Study 15730354 — intervention group
Group type: EXPERIMENTAL
Intervention: Various medications (specific medications not detailed)
Number of subjects: 398
Study 15730354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study 11874742 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT‐152 (100 microg in 100 microl)
Number of subjects: 24
Study 11874742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11874742 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT‐152
Number of subjects: 24
Study 9043535 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 7 mg over 8 hours via metered-dose inhaler (MDI) attached to a holding chamber
Number of subjects: 60
Study 9043535 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered in the same fashion as BDP
Number of subjects: 60
Study 7957146 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 kcal.24 h‐1 (7560 kJ, LC)
Number of subjects: 27
Study 7957146 — intervention group
Group type: EXPERIMENTAL
Intervention: 3200 kcal.24 h‐1 (13440 kJ, MC)
Number of subjects: 27
Study 7957146 — intervention group
Group type: EXPERIMENTAL
Intervention: 4200 kcal.24 h‐1 (17,640 kJ, HC)
Number of subjects: 27
Study 2438966 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamine/decongestant
Number of subjects: 10
Study 2438966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29787355 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender cream and footbath
Number of subjects: 141
Study 29787355 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender cream alone
Number of subjects: 141
Study 29787355 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 141
Study 27534742 — intervention group
Group type: EXPERIMENTAL
Intervention: School and household intervention combining dietary changes and increased physical activity
Number of subjects: 2500
Study 27534742 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2500
Study 24627349 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline systolic BP increase by 20 mmHg
Number of subjects: 3474
Study 24627349 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BP levels <70 mmHg with a decrease of 10 mmHg
Number of subjects: 3474
Study 24627349 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BP levels >70 mmHg
Number of subjects: 3474
Study 22435598 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 48
Study 22435598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 20335158 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) and azithromycin (10 mg/kg daily, intravenously)
Number of subjects: 90
Study 20335158 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin (10 mg/kg daily, intravenously)
Number of subjects: 90
Study 20335158 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatments (TCM and WM)
Number of subjects: 90
Study 18709590 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based educational intervention on health genealogy workshops
Number of subjects: 6
Study 18709590 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (control group)
Number of subjects: 6
Study 15780168 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose rate brachytherapy monotherapy
Number of subjects: 0
Study 15780168 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy options
Number of subjects: 0
Study 15780168 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched analyses with uniform patient treatment and pathological review
Number of subjects: 0
Study 12091849 — intervention group
Group type: EXPERIMENTAL
Intervention: abacavir/lamivudine/zidovudine
Number of subjects: 23
Study 12091849 — intervention group
Group type: COMPARATOR
Intervention: lamivudine/zidovudine
Number of subjects: 23
Study 10347106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment
Number of subjects: 225
Study 8613013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (10 mg/kg/day)
Number of subjects: 26
Study 1888818 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg famotidine nocte
Number of subjects: 208
Study 1888818 — intervention group
Group type: COMPARATOR
Intervention: 150 mg ranitidine nocte
Number of subjects: 208
Study 6401807 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (40 to 400 micrograms/kg/day)
Number of subjects: 127
Study 6401807 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper supplementation (20 or 40 micrograms/kg/day)
Number of subjects: 127
Study 6401807 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc and copper supplementation
Number of subjects: 127
Study 6401807 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference ranges for serum zinc, copper, retinol‐binding protein, prealbumin, and ceruloplasmin
Number of subjects: 127
Study 31138522 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 20,000 IU/week
Number of subjects: 208
Study 31138522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 30080254 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alcohol self-administration after 2 weeks of abstinence
Number of subjects: 50
Study 27997653 — intervention group
Group type: EXPERIMENTAL
Intervention: Pritelivir 100 mg daily for 28 days
Number of subjects: 91
Study 27997653 — intervention group
Group type: COMPARATOR
Intervention: Valacyclovir 500 mg daily for 28 days
Number of subjects: 91
Study 27997653 — intervention group
Group type: EXPERIMENTAL
Intervention: Pritelivir
Number of subjects: 91
Study 27997653 — intervention group
Group type: COMPARATOR
Intervention: Valacyclovir
Number of subjects: 91
Study 24488184 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-to-consumer advertising (DTCA) about Cymbalta (an antidepressant)
Number of subjects: 272
Study 22281110 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI and rebamipide combination therapy
Number of subjects: 290
Study 22281110 — intervention group
Group type: COMPARATOR
Intervention: PPI alone
Number of subjects: 290
Study 20418698 — intervention group
Group type: EXPERIMENTAL
Intervention: SSI-guided analgesia
Number of subjects: 80
Study 20418698 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 17425830 — intervention group
Group type: EXPERIMENTAL
Intervention: Wallace catheter
Number of subjects: 260
Study 17425830 — intervention group
Group type: COMPARATOR
Intervention: Labotect catheter
Number of subjects: 260
Study 17425830 — intervention group
Group type: EXPERIMENTAL
Intervention: Wallace catheter (as treated)
Number of subjects: 260
Study 17425830 — intervention group
Group type: COMPARATOR
Intervention: Labotect catheter (as treated)
Number of subjects: 260
Study 17425830 — intervention group
Group type: EXPERIMENTAL
Intervention: Wallace catheter (catheter change due to unsuccessful negotiation)
Number of subjects: 260
Study 17425830 — intervention group
Group type: COMPARATOR
Intervention: Labotect catheter (catheter change due to unsuccessful negotiation)
Number of subjects: 260
Study 16390780 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement (2 mg estradiol/day, orally for 90 days)
Number of subjects: 23
Study 16390780 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 23
Study 11940322 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary intracoronary stenting
Number of subjects: 98
Study 11940322 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rt-PA therapy plus rescue intracoronary stenting
Number of subjects: 98
Study 9804012 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic CT with intravenous administration of 40 ml Ioversol (5 cc/s)
Number of subjects: 19
Study 8904479 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin treatment for 'silent' PDA
Number of subjects: 290
Study 8904479 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with 'silent' PDA
Number of subjects: 290
Study 8904479 — intervention group
Group type: COMPARATOR
Intervention: Infants without PDA
Number of subjects: 290
Study 8904479 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants with 'silent' PDA unresponsive to indomethacin
Number of subjects: 290
Study 8904479 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants with 'silent' PDA responsive to indomethacin
Number of subjects: 290
Study 2797925 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (one puff, 12 micrograms)
Number of subjects: 15
Study 2797925 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (one puff, 100 micrograms)
Number of subjects: 15
Study 203832 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate and m-Inositolnicotinate (1.5 g Clofibrate and 1.2 g m-Inositolnicotinate daily)
Number of subjects: 0
Study 203832 — intervention group
Group type: COMPARATOR
Intervention: Clofibrate or clofibrinic acid (monotherapy)
Number of subjects: 0
Study 203832 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Clofibrate with m-Inositolnicotinate)
Number of subjects: 0
Study 203832 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate with nicotinic acid
Number of subjects: 0
Study 203832 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure nicotinic acid (3 to 4 g/daily) or its esters (4 to 6 g/daily) or beta-Pyridylcarbinol (800 to 1200 mg/daily)
Number of subjects: 0
Study 203832 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dosage of nicotinic acid
Number of subjects: 0
Study 30553401 — intervention group
Group type: EXPERIMENTAL
Intervention: O3-I (omega-3 index) mean 3.7±1.0%
Number of subjects: 899
Study 30553401 — intervention group
Group type: EXPERIMENTAL
Intervention: O3-I (omega-3 index)
Number of subjects: 899
Study 26216919 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice-based reality therapy
Number of subjects: 44
Study 26216919 — intervention group
Group type: COMPARATOR
Intervention: Control group (not attending the program)
Number of subjects: 44
Study 25880805 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg od
Number of subjects: 36
Study 25880805 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 23674107 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized isotonic saline (3 mL)
Number of subjects: 11
Study 23674107 — intervention group
Group type: COMPARATOR
Intervention: Nebulized water (3 mL)
Number of subjects: 11
Study 23674107 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal desiccation challenge (breathing dry air <1% relative humidity)
Number of subjects: 11
Study 22263338 — intervention group
Group type: EXPERIMENTAL
Intervention: Delmopinol rinse for 15 seconds
Number of subjects: 4
Study 22263338 — intervention group
Group type: EXPERIMENTAL
Intervention: Delmopinol rinse for 30 seconds
Number of subjects: 4
Study 22263338 — intervention group
Group type: EXPERIMENTAL
Intervention: Delmopinol rinse for 60 seconds
Number of subjects: 4
Study 22263338 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 4
Study 19695391 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg orally dispersible tablet
Number of subjects: 76
Study 19695391 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg orally dispersible tablet
Number of subjects: 76
Study 19695391 — intervention group
Group type: COMPARATOR
Intervention: Reference 100 mg capsule
Number of subjects: 76
Study 17041858 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week structured treatment interruption (STI) followed by optimized ART
Number of subjects: 41
Study 17041858 — intervention group
Group type: COMPARATOR
Intervention: Immediate optimized ART (no STI)
Number of subjects: 41
Study 15658909 — intervention group
Group type: EXPERIMENTAL
Intervention: Mersilene tape
Number of subjects: 64
Study 15658909 — intervention group
Group type: COMPARATOR
Intervention: Standard metal wire
Number of subjects: 64
Study 10654902 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose estrogen patch (0.05 mg applied twice weekly for 4 weeks)
Number of subjects: 12
Study 10654902 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose estrogen patch (0.10 mg applied twice weekly for 4 weeks)
Number of subjects: 12
Study 10168194 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient care
Number of subjects: 437
Study 10168194 — intervention group
Group type: EXPERIMENTAL
Intervention: Day care
Number of subjects: 437
Study 10168194 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary care after one week of day care
Number of subjects: 437
Study 8375373 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g lecithin.kg body mass-1 before exercise
Number of subjects: 23
Study 8375373 — intervention group
Group type: COMPARATOR
Intervention: Placebo before exercise
Number of subjects: 23
Study 8375373 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g lecithin.kg body mass-1 without exercise
Number of subjects: 23
Study 8375373 — intervention group
Group type: COMPARATOR
Intervention: No lecithin supply during running
Number of subjects: 23
Study 3093237 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg lithium carbonate daily for 3 weeks
Number of subjects: 5
Study 3093237 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 nights)
Number of subjects: 5
Study 3093237 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (3 nights during therapy)
Number of subjects: 5
Study 3093237 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment (2 registrations after lithium carbonate was discontinued)
Number of subjects: 5
Study 31725332 — intervention group
Group type: EXPERIMENTAL
Intervention: FVG
Number of subjects: 21
Study 31725332 — intervention group
Group type: EXPERIMENTAL
Intervention: FVG + CD
Number of subjects: 21
Study 29943430 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundled self‐management intervention (Taking control of your phosphate with the 4Ds)
Number of subjects: 0
Study 29943430 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 27871595 — intervention group
Group type: EXPERIMENTAL
Intervention: King Vision video laryngoscopy (KVVL)
Number of subjects: 88
Study 27871595 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 88
Study 27871595 — intervention group
Group type: EXPERIMENTAL
Intervention: King Vision video laryngoscopy (KVVL) and Direct laryngoscopy (DL)
Number of subjects: 88
Study 24814890 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (three doses)
Number of subjects: 80
Study 24814890 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular tranexamic acid
Number of subjects: 80
Study 23009373 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual training and counselling programme
Number of subjects: 90